

The invention relates to medicine, particularly to pediatric hepatology and infectious diseases and can be used for treating chronic viral hepatitis B with cholestatic syndrome in children.

Summary of the invention consists in that it is performed the basic treatment, and simultaneously is administered *per os* 5 α -furostan-3 β ,22,26-triol-3-[O- β -D-glucopyranosyl (1 \rightarrow 2)- β -D-glucopyranosyl(1 \rightarrow 4)- β -D-galactopyranosyl]-26-O- β -D-glucopyranoside) 100 mg, 2 times a day, 3-O-[β -D-glucopyranosyl(1 \rightarrow 2)]-[β -D-glucopyranosyl(1 \rightarrow 3)]-[β -D-glucopyranosyl(1 \rightarrow 4)]- β -D-galactopyranosyl[(25R)-5 α -furostan-2 α ,3 β ,22 α ,26-tetraol]-26-O- β -D-glucopyranoside 50 mg and ursodesoxycho-lic acid 15 mg/kg body weight, once a day, for 24 weeks.

Claims: 1